After FDA approval, Alkermes plans soft launch for antipsychotic LybalviThe FDA approval of Alkermes’ new antipsychotic drug Lybalvi couldn’t have gone any better for the company, but Share XAfter FDA approval, Alkermes plans soft launch for antipsychotic Lybalvihttps://pharmaphorum.com/news/after-fda-approval-alkermes-plans-soft-launch-for-antipsychotic-lybalvi/
